Trial Profile
Analysis of treatment with Ruxolitinib in Portuguese patients with myelofibrosis in a real world setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Nov 2016
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- 11 Nov 2016 New trial record
- 02 Nov 2016 Results presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research